Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial-Reference-Cited by-同舟云学术

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial

Published:2006-04 Issue:8 Volume:94 Page:1122-1129
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Cassidy J,Douillard J-Y,Twelves C,McKendrick J J,Scheithauer W,Bustová I,Johnston P G,Lesniewski-Kmak K,Jelic S,Fountzilas G,Coxon F,Díaz-Rubio E,Maughan T S,Malzyner A,Bertetto O,Beham A,Figer A,Dufour P,Patel K K,Cowell W,Garrison L P

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6603059.pdf

Reference33 articles.

1. Aballéa S, Chancellor J, Raikou M, Drummond M, Weinstein M, Brouard R, Jourdan S, Bridgewater JA (2005) Cost-effectiveness of oxaliplatin/5-FU/LV in adjuvant treatment of colon cancer in the US. Proceedings of the 2005 GI Cancers Symposium 181 (abstr 194)

2. Arkenau HT, Bermann A, Rettig K, Strohmeyer G, Porschen R, Arbeitsgemeinschaft Gastrointestinale Onkologie (2003) 5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial. Ann Oncol 14: 395–399

3. Arkenau T, Schmoll H, Kubicka S, Kretzschmar A, Freier W, Sufferlein T, Graeven U, Grothey A (2005) Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) vs capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): results of the safety and efficacy analysis. J Clin Oncol 2005 ASCO Annual Meeting Proceedings 23 (abstr 3507)

4. Borner MM, Schöffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C, Fumoleau P (2002) Patient preference and pharmacokinetics of oral modulated UFT vs intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38: 349–358

5. Chartered Institute of Public Finance and Accountancy (2005) The Health Services Database 2005. London: CIPFA/HFM

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer;European Journal of Cancer;2024-05

2. Exploring the Role of ADME for Anticancer Prodrugs;Handbook of Oncobiology: From Basic to Clinical Sciences;2024

3. Cost–Utility and Budget Impact Analyses of Oral Chemotherapy for Stage III Colorectal Cancer: Real-World Evidence after Policy Implementation in Thailand;Cancers;2023-10-11

4. Provider responses to the expansion of public subsidies in healthcare: The case of oral chemotherapy treatment in Australia;Social Science & Medicine;2023-08

5. Recent Advances in Doxorubicin Formulation to Enhance Pharmacokinetics and Tumor Targeting;Pharmaceuticals;2023-05-29